NIKKEI 225
38,641.54 +8.52 (+0.02%) HANG SENG
18,012.00 -323.32 (-1.76%) CRUDE OIL
82.34 +0.17 (+0.21%) GOLD FUTURES
2,376.20 +7.20 (+0.30%) DOW
39,134.76 +299.90 (+0.77%) Bitcoin GBP
50,912.79 -631.62 (-1.23%)
Lyell Immunopharma, Inc. (LYEL)
After hours:
| Previous close | 2.1000 |
| Open | 2.0700 |
| Bid | 2.0700 x 300 |
| Ask | 2.1000 x 400 |
| Day's range | 2.0500 - 2.1550 |
| 52-week range | 1.3200 - 3.4100 |
| Volume | |
| Avg. volume | 781,370 |
| Market cap | 534.088M |
| Beta (5Y monthly) | -0.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10 at 4:00 pm ET. A live webcast of the presentation can be accessed through the Investors section of the Company's w
- GlobeNewswire
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the BofA Securities 2024 Health Care Conference on Tuesday, May 14 at 8:40 am PT. A live webcast of the presentation can be accessed through the Investors section of the Company's website at ww
- GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarterOn track to report initial clinical data from the Phase 1 trial of LYL845, an epigenetically enhanced TIL product candidate, in the second half of 2024IND for second generation ROR1-targeted CAR T-cell product candidate on track for submission this quarterCash, cash equivalents and marketable securities of $526.3 million as of March 31, 2024 supports
